{"id":"W3123908305","doi":"10.1200/jco.2021.39.3_suppl.321","title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Cohort; Gastroenterology; Surgery; Toxicity; Cancer; Sorafenib; Clinical trial; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002718351,0.001527972,0.001402194,0.0004564734,0.0003728132,0.001371785,0.0009088403,0.001041088,0.004327909],"category_scores_gemma":[0.0008718714,0.0007169334,0.001728799,0.0004077076,0.0005675069,0.001000614,0.0005384343,0.002405109,0.001112854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001155397,"about_ca_system_score_gemma":0.001574726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009915739,"about_ca_topic_score_gemma":0.002886008,"domain_scores_codex":[0.9994053,0.0003211899,0.00002659632,0.00009417722,0.00004919504,0.0001035418],"domain_scores_gemma":[0.9994312,0.00006893263,0.0001305595,0.00004843808,0.00003605574,0.0002847217],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8462787,0.04056638,0.01835919,0.001323958,0.004122531,0.0003416365,0.0002432894,0.001789919,0.01504541,0.0003469437,0.006308064,0.06527399],"study_design_scores_gemma":[0.7702783,0.1946116,0.02560265,0.00008177881,0.00134391,0.0003589778,0.00007239503,0.0009903957,0.001190421,0.0002419969,0.005194855,0.0000326655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849197,0.004015314,0.000558531,0.0005773449,0.000139561,0.004748213,0.002386098,0.00008795364,0.00256718],"genre_scores_gemma":[0.9816912,0.002152465,0.001715967,0.001618783,0.0001776853,0.004588576,0.004784533,0.00003445612,0.00323632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004327909,"threshold_uncertainty_score":0.01447833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123646056471813,"score_gpt":0.4585702125197086,"score_spread":0.3462056068725273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}